Final consortium meeting in Innsbruck, AT
MITIGATE held its final consortium meeting at the Medical University in Innsbruck, Austria on September 12-13. The project will conclude at the end of September 2017.
Consortium members presented their results and achievements of the MITIGATE project over the past four years, and discussed opportunities on how to continue the fruitful collaboration after the funding period ends.
The MITIGATE clinical study shows promising results, and partners Advanced Accelerator Applications and the Medical University Innsbruck look to continue their collaboration in the development of nuclear medicine tracers for the diagnosis, and eventually treatment, of GIST.
MITIGATE has been highly successful in achieving the goals it set out at the beginning of the project and there are clear strategies for the future exploitation and marketing of MITIGATE results.